Drug Trial Radar · NCT03577899
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)
Last checked: Nov 20, 2026Latest source record: Jun 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,157
Actual
Start
Sep 25, 2018
Primary completion
Sep 25, 2020
Study completion May 19, 2021
Sponsor
- Lead sponsor
- Chengdu Kanghong Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 5, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept intravitreal (IVT) injection as compared to the approved vascular endothelial growth factor (VEGF) antagonist active control, aflibercept intravitreal injection (2.0 mg/eye, Eylea®), in subjects with neovascular AMD.
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
0.5 mg Conbercept Intravitreal InjectionBiological
Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.
1.0 mg Conbercept Intravitreal InjectionBiological
Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.
2.0 mg Aflibercept Intravitreal InjectionBiological
Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in best corrected visual acuity (BCVA) at Week 36 in the study eyeTime frame: Baseline to Week 36
Locations
179 sites in 22 countries. Site status is shown where the registry gives one.
Kanghong Investigative Site
Phoenix, Arizona
Kanghong Investigative Site
Tucson, Arizona
Kanghong Investigative Site
Beverly Hills, California
Kanghong Investigative Site
Campbell, California
Kanghong Investigative Site
Fullerton, California
Kanghong Investigative Site
Glendale, California
Kanghong Investigative Site
La Jolla, California
Kanghong Investigative Site
Mountain View, California
Kanghong Investigative Site
Oakland, California
Kanghong Investigative Site
Palm Desert, California
Kanghong Investigative Site
Palm Desert, California
Kanghong Investigative Site
Sacramento, California
Kanghong Investigative Site
Walnut Creek, California
Kanghong Investigative Site
Golden, Colorado
Kanghong Investigative Site
Fort Myers, Florida
Kanghong Investigative Site
Fort Myers, Florida
Kanghong Investigative Site
Jacksonville, Florida
Kanghong Investigative Site
Lakeland, Florida
Kanghong Investigative Site
Ocala, Florida
Kanghong Investigative Site
Orlando, Florida
Kanghong Investigative Site
Plantation, Florida
Kanghong Investigative Site
Sarasota, Florida
Kanghong Investigative Site
St. Petersburg, Florida
Kanghong Investigative Site
Tampa, Florida
Kanghong Investigative Site
‘Aiea, Hawaii
Kanghong Investigative Site
Bloomington, Illinois
Kanghong Investigative Site
Chicago, Illinois
Kanghong Investigative Site
Lemont, Illinois
Kanghong Investigative Site
Wichita, Kansas
Kanghong Investigative Site
Paducah, Kentucky
Kanghong Investigative Site in MD
Hagerstown, Maryland
Kanghong Investigative Site
Hagerstown, Maryland
Kanghong Investigative Site
Boston, Massachusetts
Kanghong Investigative Site
Detroit, Michigan
Kanghong Investigator Site
Bloomfield, New Jersey
Kanghong Investigative Site
Albany, New York
Kanghong Investigative Site
Hauppauge, New York
Kanghong Investigative Site
Rochester, New York
Kanghong Investigative Site
Cincinnati, Ohio
Kanghong Investigative Site
Cleveland, Ohio
Showing 40 of 179 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.